Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients

Summary

This pilot clinical trial studies the effect of pembrolizumab and lenvatinib in treating patients with high-grade serous ovarian cancers. Immunotherapy with monoclonal antibodies such as pembrolizumab may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Lenvatinib is an enzyme inhibitor that may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and lenvatinib may help to control the disease and provide an effective therapeutic option for cancer.

Timeline

Start

2021-11-09

Primary completion

2027-01-31

Completion

2027-01-31

Drugs

Indications